(fluoren-1-ylmethyl)amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (fluoren-1-ylmethyl)amine
• 英文别名: (Aminomethyl)fluorene；9H-fluoren-1-ylmethanamine
• 化学式: C₁₄H₁₃N
• 分子量: 195.264
• InChiKey: BJTMBKVDGWKSBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (fluoren-1-ylmethyl)amine 在 sodium hydroxide 、 氯甲酸乙酯 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 2-ethyl-3-[4-methoxy-3-[N-[[fluoren-1-yl]methyl]carbamoyl]phenyl]propanoic acid
  参考文献：
  名称：

  Design, synthesis, and evaluation of a novel series of α-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) α/δ dual agonists for the treatment of metabolic syndrome

  摘要：

  A series of alpha-alkyl-substituted phenylpropanoic acids was prepared as dual agonists of peroxisome proliferator-activated receptors alpha and delta (PPAR alpha/delta). Structure-activity relationship studies indicated that the shape of the linking group and the shape of the substituent at the distal benzene ring play key roles in determining the potency and the selectivity of PPAR subtype transactivation. Structure-activity relationships among the amide series (10) and the reversed amide series (13) are similar, but not identical, especially in the case of the compounds bearing a bulky hydrophobic substituent at the distal benzene ring, indicating that the hydrophobic tail part of the molecules in these two series binds at somewhat different positions in the large binding pocket of PPAR. alpha-Alkyl-substituted phenylpropanoic acids of (S)-configuration were identified as potent human PPAR alpha/delta dual agonists. Representative compounds exhibited marked nuclear receptor selectivity for PPAR alpha and PPAR delta. Subtype-selective PPAR activation was also examined by analysis of the mRNA expression of PPAR-regulated genes. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.09.001

文献信息

• NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20180009818A1

  公开（公告）日：2018-01-11

  The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): wherein A, R 2 , and X are as defined in the specification; or a salt thereof.

  本发明要解决的问题是提供一种具有RET抑制活性的新型化合物。本发明还提供了一种药物制剂，基于RET抑制活性，用于预防和/或治疗与RET相关的疾病，特别是癌症。本发明提供了一种由以下式表示的化合物：其中A、R2和X如规范中定义；或其盐。
• N.sup.6 -tricyclic adenosines for treating hypertension
  申请人：Warner-Lambert Company

  公开号：US04663313A1

  公开（公告）日：1987-05-05

  N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical composition and methods for using said compounds and compositions are described.

  本发明涉及N.sup.6-三环腺苷及其药学上可接受的酸加盐，其具有高度理想的中枢神经系统和心血管特性，描述了其制造过程、制药组合物和使用该化合物和组合物的方法。
• N.sup.6 -tricyclic adenosines
  申请人：Warner-Lambert Company

  公开号：US04593019A1

  公开（公告）日：1986-06-03

  N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are described.

  本文描述了具有高度理想的中枢神经系统和心血管特性的N.sup.6-三环腺苷及其药用酸盐加成物，以及制造这些化合物的过程和制药组合物和使用这些化合物和组合物的方法。
• DIENE POLYMER AND PROCESS FOR PRODUCING THE SAME
  申请人：OSAKADA Kohtaro

  公开号：US20080214754A1

  公开（公告）日：2008-09-04

  A polymer containing units represented by the defined formula (1); and a process for producing the polymer, which comprises the step of polymerizing a compound represented by the defined formula (3), the units represented by the formula (1) being polymerized units of the compound represented by the formula (3) such as 5,5-diallylbarbituric acid.

  一种聚合物包含由定义的公式（1）表示的单元;以及制备该聚合物的方法，其中包括聚合由定义的公式（3）表示的化合物的步骤，由公式（1）表示的单元是由公式（3）表示的化合物的聚合单元，例如5,5-二烯基苯妥拉酸。
• N6-acenaphthyl adenosines and analogs thereof
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0179630A2

  公开（公告）日：1986-04-30

  There are disclosed compounds; or a pharmaceutically acceptable acid form salt thereof; wherein R6a is hydrogen or lower alkyl; R6b is hydrogen, hydroxy, lower alkyl, lower alkanoyloxy or benzoyloxy; R6c and R6d are each, independently, hydrogen or one or more 'substituents chosen from halogen, hydroxy, lower alkoxy, lower alkanoyloxy, benzoyloxy, lower S(O)n-alkyl in which n is 0, 1, or 2, sulfonamide, trifluoromethyl, lower alkyl, lower mono- or dialkylamino, nitro or sulfhydryl; X is a valence bond or a straight or branched alkylene of from 1 to 8 carbon atoms; Y is a valence bond, oxygen, sulphur, NR in which R is hydrogen, lower alkyl, lower alkanoyl, benzoyl, -(CH2)n- in which n is 1 or 2, or -CH=CH-; R2 is hydrogen, halogen, NRIRII, ORI or SR' in which Ri and Rij are each, independently, hydrogen, lower alkyl, or phenyl lower alkyl; R2', R3, and R5 are each independently hydrogen, lower alkanoyl, benzoyl, or benzoyl substituted by lower alkl, lower alkoxy, halogen or trfluoromethyl, or R2' and R3' may be bonded together to form a lower, C-6, alkylidene group. Also disclosed are processes for their manufacture, pharmaceutical compositions and methods for using said compounds and compositions. The compounds have highly desirable central nervous system cardiovascular properties.

  有已公开的化合物； 或其药学上可接受的酸式盐；其中 R6a 是氢或低级烷基； R6b 是氢、羟基、低级烷基、低级烷酰氧基或苯甲酰氧基； R6c和R6d各自独立地为氢或一个或多个'取代基，选自卤素、羟基、低级烷氧基、低级烷酰氧基、苯甲酰氧基、低级S(O)n-烷基（其中n为0、1或2）、磺酰胺、三氟甲基、低级烷基、低级单烷基或二烷基氨基、硝基或巯基； X 是价键或 1 至 8 个碳原子的直链或支链亚烷基； Y 是价键、氧、硫、NR（其中 R 是氢、低级烷基、低级烷酰基、苯甲酰基）、-(CH2)n-（其中 n 是 1 或 2）或-CH=CH-； R2 是氢、卤素、NRIRII、ORI 或 SR'，其中 Ri 和 Rij 各自独立地是氢、低级烷基或苯基低级烷基； R2'、R3 和 R5 各自独立地为氢、低级烷酰基、苯甲酰基或被低级烷基、低级烷氧基、卤素或三氟甲基取代的苯甲酰基，或 R2' 和 R3' 可键合在一起形成低级 C-6 亚烷基。 此外，还公开了其制造工艺、药物组合物以及使用上述化合物和组合物的方法。 这些化合物具有非常理想的中枢神经系统心血管特性。